Doseology Appoints Patrick W. Sills as Strategic Go-to-Market Advisor

(TheNewswire)

Kelowna, BC – July 17,2025 – TheNewswire – Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)(“Doseology” or the “Company”), an innovator in
precision-formulated oral stimulants, is pleased to announce the
appointment of Patrick W. Sills as Strategic
Go-to-Market Advisor.

Mr. Sills is an experienced commercial strategist with
over 15 years of leadership in the nicotine and functional CPG
sectors. His career includes senior roles with Philip Morris
International and Fontem Ventures B.V., where he led initiatives in
go-to-market strategy, product commercialization, and regulatory
compliance within the nicotine pouch and reduced-risk product
categories.

Mr. Sills has contributed to the success of several
leading nicotine pouch brands and he notably led the management of the
joint venture between Philip Morris International and Swedish Match.
Through his firm, PWSILCORP, he has advised emerging brands on market
entry, distribution strategy, and regulatory pathways across North
America, Latin America, and Europe.

In his advisory role, Mr. Sills will support
Doseology’s commercialization strategy, focusing on product
positioning, distribution, regulatory considerations, and market
expansion opportunities within the Company's oral stimulant
portfolio.

Tim Corkum, President and COO of Doseology, stated,
“Patrick’s industry expertise and proven track record in executing
go-to-market strategies in highly regulated sectors will add
significant value as we continue advancing Doseology’s position in
the better-for-you nicotine and functional oral stimulant space. His
advisory role aligns with our operational priorities as we focus on
disciplined execution, accelerated market entry, and long-term
growth.”

Recent market data highlights the growing potential of
the oral nicotine pouch category. According to NielsenIQ data compiled
by Goldman Sachs Global Investment Research (June 2025), the smokeless
tobacco category—including oral nicotine pouches—grew by 13.4%
year-over-year in the most recent two-week period, driven by both
volume and pricing increases. Brands such as ZYN have gained notable
market share, underscoring a continued shift toward alternatives in
this product category. (The Company has not independently verified
this third-party data and makes no representations as to its accuracy
or completeness.)

Patrick W. Sills, Strategic Go-to-Market Advisor,
added: “This market is at a pivotal moment. The growing demand for
better-for-you alternatives presents a significant opportunity for companies that can move with
speed, precision, and a strong product offering. Doseology is
well-positioned to capitalize on this shift—not only through
go-to-market execution, but also through disciplined M&A and
roll-up strategies that expand its presence and operational scale. I
look forward to supporting the Company’s next phase of
growth.”

Chris Jackson, CEO of Doseology, added: “Our strategy
is clear: to lead innovation in the oral stimulant category with a
sharp focus on speed to market and operational excellence. Patrick’s
experience with some of the most recognized pouch brands globally will
be instrumental in helping us execute this vision and unlock long-term
value for both consumers and shareholders.”

About Doseology Sciences Inc.
(CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology is a biotech innovation company, engineeringprecision‑formulated oral stimulants that optimize energy, focus,and cognitive performance. Through rigorous scientific research andadvanced delivery technologies, we're pioneering next‑genperformance solutions designed to empower peak performance.

On behalf of the Board of Directors,

Chris Jackson

CEO

Doseology Sciences Inc.

For more information,
please contact the Company at:

Email: hello@doseology.com

Website: www.doseology.com

Phone: 604.908.3095

Forward Looking Statements

This press release contains statements that constitute“forward‐looking information” within the meaning of applicablesecurities laws. Forward‐looking information is often identified bythe words “may,” “would,” “could,” “should,”“will,” “intend,” “plan,” “anticipate,” “believe,”“estimate,” “expect” or similar expressions. Readers arecautioned that forward‐looking information is not based onhistorical facts but instead reflects the Company’s management’sexpectations, estimates or projections concerning the business of theCompany’s future results or events based on the opinions,assumptions and estimates of management considered reasonable at thedate the statements are made. Although the Company believes that theexpectations reflected in such forward‐looking information arereasonable, such information involves risks and uncertainties, andundue reliance should not be placed on such information, as unknown orunpredictable factors could have material adverse effects on futureresults, performance, or achievements. Among the key factors thatcould cause actual results to differ materially from those projectedin the forward‐looking information are the following: changes ingeneral economic, business and political conditions, including changesin the financial markets; decreases in the prevailing prices forproducts in the markets that the Company operates in; adverse changesin applicable laws or adverse changes in the application orenforcement of current laws; regulations and enforcement priorities ofgovernmental authorities; compliance with government regulation andrelated costs; and other risks described in the Company’s

prospectus. Should one or more of these risks or uncertaintiesmaterialize, or should assumptions underlying the forward‐lookinginformation prove incorrect, actual results may vary materially fromthose described herein as intended, planned, anticipated, believed,estimated, or expected. Although the Company has attempted to identifyimportant risks, uncertainties and factors which could cause actualresults to differ materially, there may be others that cause resultsnot to be as anticipated, estimated or intended. The Company does notintend, and does not assume any obligation, to update thisforward‐looking information except as otherwise required byapplicable law. For more information, investors should review theCompany’s filings which are available on SEDAR+.

No securities regulatory authority has either approvedor disapproved of the contents of this press release.

Copyright (c) 2025 TheNewswire - All rights reserved.